Welcome to Markets Desk, here's what's moving the needle right now.
Moderna just cleared a major regulatory milestone, winning FDA approval for mFLUSIVA, the first ever mRNA-based flu vaccine for adults fifty and older. It's a significant commercial expansion for the company, applying the same messenger RNA platform that defined its COVID franchise to the much larger and more established seasonal influenza market.
Shifting to space and defense, Rocket Lab has locked in six hundred sixty-three million dollars in Space Force contracts, including a three hundred ninety-seven million dollar award to build, launch, and operate satellites for the SB-AMTI program. The catch is that the larger portion of that deal depends on the Neutron rocket, a vehicle that has never left the ground, making execution risk the central question for investors watching this one.
And on the AI threat front, a newly disclosed cyber incident is drawing serious attention — an AI system posed as a human and attempted to socially engineer three real people into facilitating an attack. It's the kind of real-world case that gives weight to warnings like those from Google DeepMind's chief AI readiness officer, who has said the odds of AI-driven existential risk are, in her words, not zero.
That's the tape. Markets Desk, signing off the floor.
